Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial

A liver fibrosis index was recently prospectively validated in a cross‐sectional study where patients infected by hepatitis C virus (HCV) had only one biopsy and no longitudinal follow‐up. The aim of this study was to retrospectively assess the diagnostic value of this index in patients included in a randomized trial of interferon (IFN) using repeated measurements, two biopsies and hyaluronic acid as a comparative reference. One‐hundred and sixty‐five patients who had had two interpretable liver biopsies and at least one stored serum sample before IFN treatment were selected. Seventy‐eight patients received 3 MU of IFN‐α thrice weekly for 24 weeks and 87 followed a reinforced regimen for 48 weeks. A fibrosis index combining five biochemical markers (α2‐macroglobulin, haptoglobin, apolipoprotein A1, γ‐glutamyl transpeptidase (GGT) and total bilirubin adjusted for gender and age) as well as hyaluronic acid was assessed on 461 samples available at baseline, at the end of treatment and at the end of follow‐up (72 weeks).

[1]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[2]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[3]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[4]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[5]  G. Alexander,et al.  Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection , 1998, Journal of viral hepatitis.

[6]  S. Friedman Evaluation of fibrosis and hepatitis C. , 1999, The American journal of medicine.

[7]  G. Davis,et al.  Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C , 2000, Hepatology.

[8]  P. Bedossa,et al.  Fibrosis in Patients with Chronic Hepatitis C: Detection and Significance , 2000, Seminars in liver disease.

[9]  S. Chevret,et al.  Reinforced regiment of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomized trial , 1998 .

[10]  F. Degos,et al.  Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.

[11]  M. Vidaud,et al.  Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.

[12]  W D Carey,et al.  The role of liver biopsy in chronic hepatitis C , 2001, Hepatology.

[13]  P. Bedossa,et al.  Appropriateness of liver biopsy. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[14]  M. Arthur,et al.  Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis. , 2000 .

[15]  L. Serfaty,et al.  Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. , 1996, Clinical chemistry.

[16]  J. Dienstag,et al.  The role of liver biopsy in chronic hepatitis C , 2002, Hepatology.